| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6109135 | Journal of Hepatology | 2008 | 13 Pages |
Abstract
HCC could potentially be treated with the combination treatment of ABT-869 and rapamycin. Clinical trials on combination therapy are warranted.
Keywords
eukaryotic initiation factor 4E-binding protein 14EBP1mTORp70S6KHCCMAPKp70S6 kinaseAngiogenesisRapamycinVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)mTOR pathwayTyrosine kinase inhibitorTyrosine kinase inhibitorsmammalian target of rapamycinmitogen activated protein kinaseHepatocellular carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Viraj J. Jasinghe, Zhigang Xie, Jianbiao Zhou, Jiaying Khng, Lai-Fong Poon, Palaniyandi Senthilnathan, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen,